The Pathophysiological Role of Interstitial Sodium in Heart Failure  by Nijst, Petra et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 4 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 1 1 . 0 2 5THE PRESENT AND FUTURE
STATE-OF-THE-ART REVIEWThe Pathophysiological Role of
Interstitial Sodium in Heart Failure
Petra Nijst, MD,*y Frederik H. Verbrugge, MD,*y Lars Grieten, PHD, MSC,*y Matthias Dupont, MD,*
Paul Steels, MD,z W.H. Wilson Tang, MD,x Wilfried Mullens, MD, PHD*zABSTRACTFro
Ha
ve
Cle
UH
Lim
dis
Lis
Yo
MaThe current understanding of heart failure (HF) does not fully explain the spectrum of HF symptoms. Most HF hospi-
talizations are related to sodium (Naþ) and ﬂuid retention resulting from neurohumoral up-regulation. Recent insights
suggest that Naþ is not distributed in the body solely as a free cation, but that it is also bound to large interstitial
glycosaminoglycan (GAG) networks in different tissues, which have an important regulatory function. In HF, high Naþ
intake and neurohumoral alterations disrupt GAG structure, leading to loss of the interstitial buffer capacity and
disproportionate interstitial ﬂuid accumulation. Moreover, a diminished endothelial GAG network (the endothelial
glycocalyx) results in increased vascular resistance and disturbed endothelial nitric oxide production. New imaging
modalities can help evaluate interstitial Naþ and endothelial glycocalyx integrity. Furthermore, several therapies have
been proven to stabilize interstitial GAG networks. Hence, a better appreciation of this new Naþ “compartment” might
improve current management of HF. (J Am Coll Cardiol 2015;65:378–88) © 2015 by the American College of Cardiology
Foundation.A pproximately 90% of heart failure (HF) hos-pitalizations are associated with signs andsymptoms of sodium (Naþ) and ﬂuid excess,
which are associated with disease progression and a
worse prognosis (1,2). Traditionally, the primary
abnormality in HF was understood to be Naþ
handling, whereby water movement passively fol-
lows Naþ to keep osmolality in balance. Due to neuro-
humoral up-regulation and increased arginine
vasopressin (AVP) production, the kidneys are not
capable of adjusting Naþ excretion to Naþ intake.
The resulting imbalance leads to Naþ accumulation,
followed by interstitial and intravascular volume
retention, and, eventually, to edema and increased
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(ADHF), patients display a wide spectrum of weight
changes, with <50% gaining substantial weight (>1
kg) (4). Moreover, although a signiﬁcant increase in
cardiac ﬁlling pressure is consistently observed days
before an ADHF admission, a broad range of plasma
volumes has been observed in ADHF patients (5,6).
Finally, total body Naþ levels were found to be
increased in observational studies of HF from >60
years ago (7). Interestingly, this increase was found
in patients both with overt peripheral edema and
without edema (8,9). Important changes in total
body Naþ occur over extended periods of time, even
in healthy individuals on a stable Naþ diet, and are
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AB BR E V I A T I O N S
AND ACRONYM S
ADHF = acute decompensated
heart failure
AVP = arginine vasopressin
eGC = endothelial glycocalyx
EnNaC = endothelial
sodium channel
GAG = glycosaminoglycan
HF = heart failure
Naþ = sodium
NO = nitric oxide
TBW = total body water
VEGF-C = vascular endothelial
growth factor C
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379(TBW) (10,11). Therefore, the classic idea of simulta-
neous Naþ and ﬂuid retention may not always be
true as an explanation for ﬂuid overload and
increased cardiac ﬁlling pressures in ADHF.
Recent evidence has demonstrated that a large part
of total body Naþ is bound to glycosaminoglycan
(GAG) networks in the interstitium; these GAG net-
works function as Naþ buffers and play an important
role in ﬂuid homeostasis and endothelial function.
This review aims to provide insight in the important
physiological role of interstitial Naþ bound to GAGs in
preserving Naþ and ﬂuid regulation, as well as
endothelial function. A better understanding of the
contributory role of interstitial Naþ across the spec-
trum of HF presentations may shed light on a novel
therapeutic target that has otherwise been
overlooked.
THE BODY TIGHTLY REGULATES
SODIUM AND WATER BALANCE
A typical Western diet contains approximately 12 g of
salt (Naþ chloride) per day, which is equivalent to the
approximately 4.5 g (approximately 200 mmol) of Naþ
that is almost completely absorbed in the gastrointes-
tinal system. The plasma Naþ concentration and
osmolality start to rise 30 to 60 min after an oral Naþ
load (12). Because the body tightly regulates osmolality
through osmoreceptors in the hypothalamus, a rise of
even a few milliosmoles per liter in plasma osmolality
results in retention of free water through stimulation
of thirst and AVP release. Baroreceptors in the large
(aortic arch, carotid sinus) and small vasculature
(pulmonary vasculature, renal afferent arteriole) sub-
sequently sense a rise in TBW to modulate urinary Naþ
and water excretion. From the plasma, Naþ is freely
ﬁltered in the renal glomerulus. Because tubular Naþ
reabsorption exceeds 99%, only a tiny fraction of Naþ is
excreted in the urine. In normal circumstances,
extrarenal Naþ loss from skin (sweat) and from the
gastrointestinal tract (feces) is negligible. Neverthe-
less, because relatively small changes in Naþ excretion
by the kidneys can lead to marked alterations in TBW
(13), this tiny fraction of renal Naþ excretion is highly
regulated to mimic dietary intake.
SODIUM BUFFERING BY
GLYCOSAMINOGLYCANS
On the basis of intracellular and extracellular Naþ
concentrations, approximately 65% of total body Naþ
is assumed to reside in the extracellular ﬂuid (plasma
ﬂuid and interstitial ﬂuid), whereas only 5% to 10% is
found in the intracellular ﬂuid (13). The remaining
25% of total body Naþ is sequestered in bone as Naþapatites and is not readily exchangeable, in
contrast to Naþ in the extracellular and
intracellular ﬂuid compartments.
Contemporary evidence indicates that Naþ
cations are largely bound to negative bio-
polymers, called glycosaminoglycans (GAGs)
(14,15). GAGs are linear polymers of disac-
charide units with variable lengths that are
modiﬁed by sulfation and/or acetylation and/
or deacetylation. Thus, all GAGs have nega-
tive charges in the form of carboxyl and/or
sulfate groups (Central Illustration) (16).
Multiple GAG chains can anchor to a linear
linking protein, forming a large brush-shaped
proteoglycan that contains numerous anionic
charges. They are connected via intra-
molecular hydrogen bonds to form a compact
macromolecule (17). The extremely polyanionic na-
ture of these macromolecules leads to electrostatic
interactions between their negatively charged sur-
faces, such as collagen ﬁbrils, proteins, and positive
electrolytes, thus creating a network with a high
oncotic pressure. In vitro studies have observed that
the interaction with Naþ, the most abundant cation of
the extracellular compartment, is favored over other
ions and proteins (18). Consequently, a large amount
of Naþ is bound to GAGs, creating a microenviron-
ment of hypertonic Naþ concentration (19). However,
the dense network exhibits a low compliance, sec-
ondary to its strong elastic and tensile force, thereby
“pressing” ﬂuid out. Importantly, disruption of bonds
within GAGs or alterations in bound molecules will
have signiﬁcant structural and functional conse-
quences for the proteoglycans (20,21).
INTERSTITIAL SODIUM
SODIUM ACCUMULATES DYNAMICALLY IN INTERSTITIAL
GLYCOSAMINOGLYCAN NETWORKS. The interstitium
connects and supports tissues while serving as a
transport medium for nutrients, waste products, and
signaling molecules. GAGs are the main constituents
of the interstitium of various tissues (22–24).
Together with collagen and/or elastin ﬁbers, they
comprise the solid phase and determine the structure
and compliance of the interstitium (22,25). Because 1
GAG macromolecule can bind a large quantity of Naþ
cations, the interstitium can accumulate or buffer a
high amount of Naþ (Figure 1A) (26). Data from long-
term balance studies in humans have conﬁrmed that
considerable amounts of Naþ accumulate in the
interstitium, particularly in skin and muscle tissue,
without compensatory water retention or changes in
plasma Naþ concentration (11,27,28). Kopp et al.
CENTRAL ILLUSTRATION Interstitial Sodium in Heart Failure: Proteoglycans and Glycosaminoglycans
Proteoglycans are the major structural components of the interstitium of different tissues and the ﬁrst endothelial layer (the endothelial glycocalyx). They consist
of multiple glycosaminoglycans (GAGs) attached to a linking protein. GAGs are linear polymers of disaccharide units that are modiﬁed by sulfation and/or acetylation
and/or deacetylation and have ﬁxed negative charges in the form of carboxyl (COO) and sulfate (SO3
) groups. The polyanionic nature of the GAG network leads to
electrostatic interactions with different molecules, particularly sodium (Naþ) cations.
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380recently quantiﬁed Naþ concentrations in skin and
muscle on the basis of 23Na-magnetic resonance im-
aging spectroscopy. Their data suggested that, in
contrast to a very stable plasma Naþ concentration,
the tissue Naþ content in humans is highly variable,
and that these variations are not accompanied by
changes in tissue ﬂuid content (15,29). As a conse-
quence, in both normal circumstances and compen-
sated HF states, interstitial GAG networks “smooth”
ﬂuctuations in plasma Naþ concentrations, and
therefore, conceal Naþ ions from the pituitary
osmoreceptors, preventing AVP release and thus
preventing water retention. Moreover, because these
secluded Naþ cations do not reach the renal nephron,
they also escape renal regulatory function and are
more difﬁcult to remove from the body.
In vitro studies have also shown that the intersti-
tial GAG network can adapt to short periods of highersalt intake, because a high concentration of Naþ cat-
ions changes the sulfation pattern and increases GAG
charge density (17,30). High Naþ concentrations also
promote gene expression of GAG polymerization en-
zymes, which further increases GAG content, and
thus, activates a positive feedback pathway to expand
Naþ storage capacity (Figure 1B) (10). In the reverse
situation of salt scarcity, GAG polymerization and
sulfation are reduced, and a subsequent reduction in
the matrix is associated with gradual mobilization of
Naþ from tissue reservoirs (19).
However, if an excessively high Naþ concentration
in the GAG network is prolonged, the conformation of
the macromolecules will eventually be altered, lead-
ing to a dysfunctional GAG network, which results in
a loss of interstitial network integrity and buffering
capacity (Figure 1C). The loss of interstitial buffering
capacity may be especially important in salt-sensitive
FIGURE 1 The Interstitium
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(A) The interstitium consists of a network of proteoglycans and collagen and/or elastin ﬁbers that determine its compliance. Interstitial ﬂuid is formed by transcapillary
ﬁltration of plasma ﬂuid and is subsequently drained by many lymphatic vessels. (B) High dietary sodium (Naþ) intake leads to an interstitium with a large glycos-
aminoglycan (GAG) network, which can accumulate a higher concentration of Naþ (and proteins), thus creating a higher interstitial oncotic pressure. A high interstitial
sodium concentration acts as a positive stimulus for lymphangiogenesis through tissue vascular endothelial growth factor-C (VEGF-C) and nitrous oxide (NO) production.
Due to the low interstitial compliance and increased lymphatic capacity, interstitial ﬂuid is efﬁciently drained, and there is no interstitial ﬂuid accumulation; however,
interstitial oncotic pressure is high (compensated state). (C)When the conformation of the GAGs is altered, the GAG network becomes dysfunctional, and the interstitium
enters a high-compliance state. Furthermore, high interstitial oncotic pressure (as with high salt intake) favors transcapillary ﬁltration of interstitial ﬂuid. In addition, due
to widening of lymphatic vessels and disturbance of propagation coordination, lymphatic drainage becomes less efﬁcient, leading to lymph extravasation. Therefore, in
heart failure (HF), interstitial ﬂuid can accumulate (decompensated state), even in patients with mildly elevated venous pressures.
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381hypertension and in neurohumoral activation in HF
(31,32).
INTERSTITIAL FLUID TRANSPORT IS REGULATED BY
INTERSTITIAL SODIUM MICROENVIRONMENTS. As
stipulated previously, GAGs create a high osmotic
pressure microenvironment (22). Therefore, subjects
with a more dense interstitial GAG network—and
consequently with a higher interstitial oncotic pres-
sure (pI)—will have more ﬁltration of plasma ﬂuid
over the capillary membrane into the interstitium.
However, the limited elastic properties (and thus, low
compliance) of the interstitial GAG network prevent
ﬂuid accumulation (33,34). Small increases in inter-
stitial ﬂuid content lead to important increases in
interstitial tensile stress. This forces interstitial ﬂuid
into the gaping lymphatic vessels. As ﬂuid quickly
drains into the systemic circulation, interstitial hy-
drostatic pressure remains low, and oncotic pressure
remains high (compensated state) (Figure 1B). More-
over, subcutaneous tissue macrophages can sensehigh Naþ concentrations and react by expressing
tonicity enhancer binding protein (TonEBP) (19),
which is a transcription factor that regulates the
expression of osmoprotective genes in response to
osmotic stress. Vascular endothelial growth factor C
(VEGF-C), a potent inducer of lymphatic vessel for-
mation and endothelial nitric oxide (NO) synthase
expression, is 1 of the genes induced by the tonicity
enhancer binding protein, further stimulating lym-
phangiogenesis (35,36). Higher VEGF-C levels and
robust lymphatic vessel hyperplasia in the dermal
interstitium have been found in response to high-salt
feeding (37,38).
INTERSTITIAL EDEMA FORMATION DEPENDS ON
INTERSTITIAL MATRIX COMPOSITION. Interstitial
ﬂuid accumulates when the rate of transudation from
capillaries into the interstitium exceeds the rate at
which the lymphatic system can efﬁciently drain
the ﬂuid. Venous pressure, more than arterial pres-
sure, increases capillary hydrostatic pressure (13).
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382Therefore, increased central venous pressure and
pulmonary capillary wedge pressure in HF promote
interstitial ﬂuid accumulation. In response, lymphatic
capacity gradually increases, parallel to a rise in
venous pressure, and only in higher ranges of venous
pressures is the return of lymph to the great veins
impeded (39,40). However, although patients with
decompensated HF always present with elevated
ﬁlling pressures (8), the occurrence of pulmonary and
peripheral edema are correlated poorly with pulmo-
nary capillary wedge pressure and central venous
pressure, respectively (8,41,42). Other factors in
addition to increased capillary pressure must play a
more important role in determining the occurrence of
edema.
As described by the Starling equation, high inter-
stitial oncotic (pI) pressures and low interstitial hy-
drostatic pressures promote transudation of plasma
ﬂuid into the interstitium, whereas low interstitial
compliance opposes ﬂuid accumulation. A prolonged,
excessively high Naþ concentration leads to a dense
interstitial GAG network with the accumulation
of Naþ cations (high pI) and an altered conformation
of the GAG macromolecules, creating a dysfunc-
tional GAG network. This may result in decreased
tensile stress, and thus, a high compliance state
of the interstitial matrix (Figure 1C). The combina-
tion of high interstitial oncotic pressure and highothelial Glycocalyx
en
Adhesion molecule Sodium Glycosaminoglycan
SPIRONOLACTONE
High [Na+]
NATRIURETIC PEPTIDE
OXIDATIVE STRESS
INFLAMMATION
Shear Stress
ocalyx (eGC) is a network of glycosaminoglycans (GAGs) connected to
thelium by adhesion molecules. It acts as a mechanotransducer and
g epithelium from blood cells. Moreover, due to the net negative
arged molecules, such as sodium (Naþ) and plasma-derived proteins,
ide the GAG network, creating a buffer and a high internal oncotic
ill be shed by inﬂammation, oxidative stress, natriuretic peptides, and
ion, whereas spironolactone has protective effects.compliance facilitates ﬂuid transudation (34). Im-
portantly, spironolactone stabilizes altered GAGs,
suggesting that unrestrained neurohumoral stimula-
tion in HF further contributes to the dysfunction
of the GAG network (43,44). Moreover, lymphatic
vessel integrity is altered as lymph vessels start
to widen, leading to leakage of lymph into the
interstitium (Figure 1C) (40). Thus, when inter-
stitial GAG networks become dysfunctional, even
mildly elevated venous pressures in HF might lead
to pulmonary congestion and peripheral edema
(decompensation).
SODIUM AND ENDOTHELIAL FUNCTION
THE ENDOTHELIAL GLYCOSAMINOGLYCAN NETWORK
CONTROLS ENDOTHELIAL FUNCTION. The endothe-
lial glycocalyx (eGC) (the inner fragile layer of
the endothelium), which is a highly specialized
variant of interstitium, is composed of a network of
membrane-bound and different types of soluble
proteoglycans (mostly heparin sulfate) and glyco-
proteins that are connected to the endothelial cell
membrane through adhesion molecules. A dynamic
equilibrium exists between the eGC and ﬂowing
blood, which continuously affects the composition
and thickness of the eGC (43,45). Both endothelium-
and plasma-derived soluble molecules (e.g., albu-
min, proteins, ions) interact with this mesh
(Figure 2) (46).
The eGC has multiple vasoprotective functions,
and it shields the underlying apical side of the
endothelium from the plasma. It reduces vascular
permeability, restricts molecules from reaching the
endothelium, and prevents interaction of platelets
and leucocytes with endothelial cell adhesion mole-
cules (47,48). Moreover, the endothelial GAG network
acts as a Naþ buffer by binding positively charged Naþ
cations (49). Naþ reversibly binds and dissociates
from eGC binding sites. As a result, the eGC buffer
allows gradual passage of Naþ from the blood into the
space between the eGC and endothelium (50). Naþ
can subsequently enter the endothelial cell through
apical endothelial Naþ channels (EnNaCs), which are
almost identical to epithelial Naþ channels. Then,
sodium-potassium adenosine triphosphatease (Naþ/
Kþ -ATPase) pumps at the basolateral side will quickly
try to restore cell homeostasis by creating a trans-
cellular passage for Naþ into the interstitium (13).
However, most Naþ is transported between endothe-
lial cells along its electrochemical gradient via the
paracellular pathway. Importantly, the eGC also acts
as a mechanotransducer, transmitting shear stress
signals into speciﬁc cell signaling processes in the
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383endothelial cell, and inﬂuencing NO production and
cytoskeletal reorganization (45,51).
HIGH INTRAENDOTHELIAL SODIUM CONCENTRATION
REDUCES NITRIC OXIDE PRODUCTION. Naþ uptake
in the endothelial cell is promoted if the abun-
dance of EnNaC in the apical membrane increases
and/or EnNaC channel activity is stimulated. This
occurs when the plasma Naþ concentration increases
(Figure 3) (52). Furthermore, high concentrations of
aldosterone (as observed in HF) trigger rapid mem-
brane insertion of pre-formed EnNaC complexes
residing in vesicles just beneath the plasma mem-
brane (53). As a consequence, Naþ uptake into endo-
thelial cells is stimulated in HF patients, especially
those on high-salt diets. Importantly, even minor
elevations in Naþ inﬂux into the endothelial cell
through EnNaCs have large consequences for endo-
thelial stiffness and NO production (54,55). Recent
atomic force microscopy studies have observed that
the endothelial cell stiffens within minutes of an
acute elevation of intraendothelial Naþ concentra-
tions (52). This acute endothelial cell reaction is
mediated by interactions between EnNaCs and cyto-
skeletal proteins (actin) in the endothelial cell sub-
membraneous cortical cytoskeleton (Figure 3) (56).FIGURE 3 Endothelial Dysfunction
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nitrous oxide synthase; Naþ/Kþ pump ¼ sodium-potassium adenosine trNaþ entry via EnNaCs also reduces endothelial NO
synthase activity via the PI3K/AKT signaling pathway
(57–59). In addition, Naþ up-regulates the endoge-
nous inhibitor of NO synthase, which is asymmetrical
dimethyl-L-arginine. Both result in decreased NO
levels (a hallmark of endothelial dysfunction) and
impair relaxation of the smooth muscle cells sur-
rounding the vessels (52,60). This plays an important
role in endothelial dysfunction, on top of the loss of
mechanotransduction of shear stress when the eGC is
diminished.
SODIUM AND NATRIURETIC PEPTIDES DISRUPT THE
ENDOTHELIAL GLYCOCALYX. Prolonged plasma Naþ
concentrations in the high physiological range (>140
mmol/l) damage the eGC. In an original in vitro
experiment, Oberleithner et al. showed that Naþ
overload changes the negatively charged sulfate res-
idues in the eGC, which results in eGC dysfunction
(43). Interestingly, spironolactone prevented these
harmful effects of Naþ on the eGC (43). Furthermore,
it is well known the eGC can be severely damaged
by inﬂammation, ischemia and/or reperfusion,
oxidative stress, excessive shear stress, and enzy-
matic degradation, all of which are common in HF
(45,61). Intriguingly, several animal studies haveSMOOTH MUSCLE CELL CONTRACTION
eNOSNOSodium cation
NO Stiff
Cytoskeleton
ermeability (dotted arrow), diminished sodium (Naþ) buffer capacity,
aþ concentrations and high aldosterone concentration promote the
rane of endothelial cells. Naþ subsequently activates EnNaCs, altering
l. High EnNaC activity and disturbed mechanotransduction inﬂuence
ion, a characteristic of endothelial dysfunction. eNOS ¼ endothelial
iphosphatease pump; NO ¼ nitrous oxide.
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384demonstrated that the natriuretic peptides (atrial,
brain, and C-type) disrupt the eGC (62,63). In an
elegant in vivo model, physiological doses of natri-
uretic peptides were observed to lead to shedding of
the eGC, as assessed by venous washout of glycocalyx
constituents (syndecan [an endothelial proteoglycan]
and heparin sulfate) and morphologically conﬁrmed
electron microscopic changes in eGC integrity (63).
Oberleithner et al. (43) further demonstrated that
Naþ overload leads to increased intracellular endo-
thelial Naþ concentrations. It is speculated that Naþ
will not be buffered when the eGC is damaged, and
instead of a gradual presentation to the underlying
endothelium, large amounts of Naþ cations will reach
the apical side of the endothelium and intercellular
clefts at once. This enhances the activity of EnNaCs,
which alters endothelial mechanical properties and
function, and promotes paracellular Naþ transport to
the interstitial space, which contributes to interstitial
ﬂuid accumulation.
A DYSFUNCTIONAL ENDOTHELIAL GLYCOCALYX
RESULTS IN VASCULAR DYSFUNCTION. In vitro ex-
periments conﬁrmed that inadequate responses to
shear stress variations and impairedNOproduction are
noticedwhen the eGC is disrupted (64). It iswell known
that, compared with healthy subjects, endothelium-
dependent NO-mediated vasodilation is impaired in
skeletal muscle and in the coronary and pulmonary
circulations of patients with chronic HF (65–67).
Overall, the lack of NO increases vascular smooth
muscle tone and consequently increases vascular
resistance (68). Increased arteriolar resistance results
in increased cardiac afterload, which often character-
izes ADHF. In this respect, multiple studies have
observed that arterial stiffening signiﬁcantly improves
with dietary salt reduction (69,70). Furthermore,
in vivo experiments have shown that high salt intake
and deﬁcient NO production also leads to a higher tone
in the venous side of the vasculature (71–74). Impor-
tantly, the largest part of total blood volume—about
three-fourths—resides in veins and venules (13).
Similar to autonomic regulated venous constriction
(75), a dysfunctional eGC might also contribute to the
shift of ﬂuid from the venous reservoir into the effec-
tive circulatory volume. Finally, when the eGC is dis-
rupted, vascular permeability increases, and plasma
ﬂuid extravasation into the interstitium of different
tissues is no longer impeded (76,77).
In conclusion, a dysfunctional eGC contributes to
the increased cardiac ﬁlling pressures in HF patients,
which may be an important contributor to decom-
pensation, because it consistently precedes ADHF
admissions (78,79).TARGETING INTERSTITIAL SODIUM IN
HEART FAILURE
Current strategies assume enhanced Naþ excretion
with diuretics or antagonizing neurohumoral up-
regulation to effectively achieve Naþ homeostasis at
the level of the nephron. However, mortality and re-
hospitalization rates for HF remain tremendously
high (1). Because the interstitial compartment also
plays an important role in Naþ and ﬂuid homeostasis
of the body, further understanding of this new
“compartment” is of great interest. Moreover, pres-
ervation and restoration of normal GAG function in
the interstitium, as well as in the eGC, could be
interesting new strategies in HF management.
First, identifying dysfunctional interstitial GAG
networks and a disrupted eGC may predict HF
patients at a higher risk for decompensation. Because
persistent signs of Naþ and ﬂuid overload in HF
are important predictors of mortality and HF
re-hospitalization, interstitial Naþ content might be a
good indicator to guide therapy and might be a new
cardiovascular risk factor (80,81). A recently devel-
oped imaging technique, 23Naþ magnetic resonance
imaging, makes it possible to assess the Naþ content of
different tissues or in the whole body, and to monitor
Naþ evolution during therapy (15). Furthermore, there
are currently several methods to determine eGC
integrity, such as measurements of the products shed
in plasma (e.g., syndecan or heparin sulfate) or visu-
alization of the eGC with sidestream dark-ﬁeld imag-
ing (videomicroscopy). This technique makes it
possible to directly visualize the microcirculation and
to detect changes in glycocalyx volume on the basis of
in vivo recordings of the sublingual microvasculature
(Figure 4) (82–84).
Second, because the eGC plays an important pro-
tective role in the maintenance of a normal endo-
thelial function and vascular permeability, stabilizing
or restoring this speciﬁc GAG network is an inter-
esting new therapeutic target. Preliminary data have
shown that in the acute inﬂammatory and proteolytic
situation of a myocardial infarction, hydrocortisone
might help to sustain the vascular barrier function,
and possibly, abrogate damage to the glycocalyx
(85,86). A potential area of further research is to
determine whether this strategy prevents eGC dam-
age when high levels of natriuretic peptides circulate
in ADHF. There is renewed interest in sulodexide,
which is an old drug, in the ﬁelds of nephrology
and vascular medicine. It is a mixture of naturally
occurring GAG components (20% dermatan sulfate,
80% heparin sulfate) that can be given orally or
FIGURE 4 Sidestream Dark Field Videomicroscopy of the Microcirculation
DISRUPTED eGC
NORMAL eGC
Real-time image of the sublingual microvasculature obtained with a hand-held videomicroscope (left panel). Moving red blood cells (RBCs) can
be directly visualized in arterioles, capillaries, and venules. Differentiation is based on the vessel width and ﬂow direction. Post hoc software
analyses allow assessment of the integrity of the endothelial glycocalyx (eGC) based on the mean distance between RBCs and the vessel
wall—and thus mean height of the eGC (blue bars/arrows)—and the appearance of the ﬂow of RBCs in the capillaries (aligned and homoge-
nously distributed along the capillary when the eGC functions properly vs. inhomogeneously distributed when the eGC is disrupted) (right panel)
(82–84).
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385intravenously, and was originally used as an antico-
agulant. After modiﬁcation and reduction of its anti-
coagulant activity, sulodexide also restores the eGC
(87,88). Various mechanisms could be responsible,
such as its anti-inﬂammatory effects, its promotion of
synthesis and sulfation of endogenous GAGs and
proteoglycans, and its antiproliferative properties
(89,90).
Dietary Naþ reduction is currently a simple (and
probably the most important) way to prevent endo-
thelial dysfunction and the interstitial Naþ accumu-
lation that causes GAG dysfunction. Dietary intake is
associated with a higher cardiovascular mortality and
more ADHF events in stable HF patients (91,92).
Furthermore, a reduction in Naþ intake can lead to a
signiﬁcant decrease in plasma Naþ (1.5 to 3.0 mmol/l)
and possibly restore dysfunctional GAG networks
(93). In this regard, a meticulous change in dietary
Naþ intake alone can reverse vascular endothelial
dysfunction and improve vascular compliance
(94,95).
When edema is present, current applied therapies in
ADHF (loop diuretics and ultraﬁltration) target free
Naþ cations andwater in the plasma compartment. It is
currently not clear how they inﬂuence interstitial Naþ
and GAGs. However, spironolactone has proven
beneﬁcial effects that extend beyond its natriuretic
effect. Kopp et al. (29) observed that spironolactone
induced a large reduction in tissue Naþ in hypertensivesubjects with high aldosterone levels. This recom-
mendation could seem futile because mineralocorti-
coid receptor antagonists are currently part of general
HF management. However, despite their widely
demonstrated beneﬁcial effects in patients with HF
with reduced ejection fractions, mineralocorticoid re-
ceptor antagonists are signiﬁcantly underused, espe-
cially during ADHF, when further mobilization of
interstitial Naþ may be essential (96,97). Spi-
ronolactone also protects the eGC and inﬂuences
downstream negative endothelial consequences of
Naþ overload, because it diminishes EnNaC surface
abundance and increases endothelial NO production
in vitro (43,98).
CONCLUSIONS
The interstitium plays an important role in Naþ and
ﬂuid homeostasis. Naþ is distributed in the body as
free cations and bound to networks of negatively
charged biopolymers, GAGs, in the interstitium of
different tissues. These interstitial GAG networks
function as Naþ buffers, regulating interstitial ﬂuid
accumulation, lymphatic vessel formation, and
endothelial function. Long-term Naþ overload and
neurohumoral up-regulation in HF cause dysfunction
of interstitial GAG networks, resulting in increased
vascular resistance and permeability, as well as
edema. Additional studies are needed to assess if
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386interstitial Naþ content is more than just an amenable
cardiovascular risk factor. Appraisal of this Naþ
compartment may provide new therapeutic strategies
that target interstitial network dysfunction and eGC
integrity, thereby reducing the burden of HF.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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